Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Therapeutically administered ribonucleoside analogue MK-4482/EIDD-2801 blocks SARS-CoV-2 transmission in ferrets
Robert M. Cox, Josef D. Wolf, Richard K. Plemper
Nature Microbiology (2020) Vol. 6, Iss. 1, pp. 11-18
Open Access | Times Cited: 383

Showing 26-50 of 383 citing articles:

Molnupiravir: A new candidate for COVID‐19 treatment
Fariba Pourkarim, Samira Pourtaghi‐Anvarian, Haleh Rezaee
Pharmacology Research & Perspectives (2021) Vol. 10, Iss. 1
Open Access | Times Cited: 110
Drug combination therapy for emerging viral diseases
Zeenat A. Shyr, Yu‐Shan Cheng, Donald C. Lo, et al.
Drug Discovery Today (2021) Vol. 26, Iss. 10, pp. 2367-2376
Open Access | Times Cited: 109
Adult stem cell-derived complete lung organoid models emulate lung disease in COVID-19
Courtney Tindle, Mackenzie Fuller, Ayden G. Fonseca, et al.
eLife (2021) Vol. 10
Open Access | Times Cited: 104
Optimal dose and safety of molnupiravir in patients with early SARS-CoV-2: a Phase I, open-label, dose-escalating, randomized controlled study
Saye Khoo, Richard J. Fitzgerald, Tom Fletcher, et al.
Journal of Antimicrobial Chemotherapy (2021) Vol. 76, Iss. 12, pp. 3286-3295
Open Access | Times Cited: 104
Randomized Trial of Molnupiravir or Placebo in Patients Hospitalized with Covid-19
José Ramón Arribas, Sanjay Bhagani, Suzana M. Lobo, et al.
NEJM Evidence (2021) Vol. 1, Iss. 2
Closed Access | Times Cited: 104
Two Years into the COVID-19 Pandemic: Lessons Learned
Severino Jefferson Ribeiro da Silva, Jéssica Catarine Frutuoso do Nascimento, Renata Pessôa Germano Mendes, et al.
ACS Infectious Diseases (2022) Vol. 8, Iss. 9, pp. 1758-1814
Open Access | Times Cited: 103
Molnupiravir and Its Antiviral Activity Against COVID-19
Lili Tian, Zehan Pang, Maochen Li, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 102
Mechanical control of innate immune responses against viral infection revealed in a human lung alveolus chip
Haiqing Bai, Longlong Si, Amanda Jiang, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 96
Animal models in SARS-CoV-2 research
Hin Chu, Jasper Fuk‐Woo Chan, Kwok‐Yung Yuen
Nature Methods (2022) Vol. 19, Iss. 4, pp. 392-394
Open Access | Times Cited: 88
4′-Fluorouridine is an oral antiviral that blocks respiratory syncytial virus and SARS-CoV-2 replication
Julien Sourimant, Carolin M. Lieber, Megha Aggarwal, et al.
Science (2022) Vol. 375, Iss. 6577, pp. 161-167
Open Access | Times Cited: 87
Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Patients
Dinah V. Parums
Medical Science Monitor (2022) Vol. 28
Open Access | Times Cited: 81
Antiviral Drug Discovery for the Treatment of COVID-19 Infections
Teresa I. Ng, Ivan Correia, Jane Seagal, et al.
Viruses (2022) Vol. 14, Iss. 5, pp. 961-961
Open Access | Times Cited: 78
Novel cleavage sites identified in SARS-CoV-2 spike protein reveal mechanism for cathepsin L-facilitated viral infection and treatment strategies
Miao-Miao Zhao, Yun Zhu, Li Zhang, et al.
Cell Discovery (2022) Vol. 8, Iss. 1
Open Access | Times Cited: 78
Advances and gaps in SARS-CoV-2 infection models
César Muñoz‐Fontela, Lina Widerspick, Randy A. Albrecht, et al.
PLoS Pathogens (2022) Vol. 18, Iss. 1, pp. e1010161-e1010161
Open Access | Times Cited: 77
Molnupiravir: First Approval
Yahiya Y. Syed
Drugs (2022) Vol. 82, Iss. 4, pp. 455-460
Open Access | Times Cited: 77
Oral antiviral treatments for COVID-19: opportunities and challenges
Laila Rahmah, Sunny O. Abarikwu, Amanuel Godana Arero, et al.
Pharmacological Reports (2022) Vol. 74, Iss. 6, pp. 1255-1278
Open Access | Times Cited: 70
The mechanism underlying extrapulmonary complications of the coronavirus disease 2019 and its therapeutic implication
Qin Ning, Di Wu, Xiaojing Wang, et al.
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 69
Sulforaphane exhibits antiviral activity against pandemic SARS-CoV-2 and seasonal HCoV-OC43 coronaviruses in vitro and in mice
Alvaro A. Ordoñez, C. Korin Bullen, A.F. Villabona-Rueda, et al.
Communications Biology (2022) Vol. 5, Iss. 1
Open Access | Times Cited: 69
Combination therapy with nirmatrelvir and molnupiravir improves the survival of SARS-CoV-2 infected mice
Ju Hwan Jeong, Santosh Chokkakula, Seong Cheol Min, et al.
Antiviral Research (2022) Vol. 208, pp. 105430-105430
Open Access | Times Cited: 67
SARS‐CoV‐2 in animals: susceptibility of animal species, risk for animal and public health, monitoring, prevention and control
José L. Gonzáles, Denise A. Marston
EFSA Journal (2023) Vol. 21, Iss. 2
Open Access | Times Cited: 45
SARS-CoV-2 immunity in animal models
Chen Zhao, Yaochang Yuan, Qing‐Tao Hu, et al.
Cellular and Molecular Immunology (2024) Vol. 21, Iss. 2, pp. 119-133
Open Access | Times Cited: 14
SARS-CoV-2 Drug Resistance and Therapeutic Approaches
Sania Batool, Santosh Chokkakula, Ju Hwan Jeong, et al.
Heliyon (2025) Vol. 11, Iss. 2, pp. e41980-e41980
Open Access | Times Cited: 3
Glycopeptide antibiotic teicoplanin inhibits cell entry of SARS-CoV-2 by suppressing the proteolytic activity of cathepsin L
Fei Yu, Ting Pan, Feng Huang, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2020)
Open Access | Times Cited: 122
Current Strategies of Antiviral Drug Discovery for COVID-19
Miao Mei, Xu Tan
Frontiers in Molecular Biosciences (2021) Vol. 8
Open Access | Times Cited: 96
Design and development of an oral remdesivir derivative VV116 against SARS-CoV-2
Yuanchao Xie, Wanchao Yin, Yumin Zhang, et al.
Cell Research (2021) Vol. 31, Iss. 11, pp. 1212-1214
Open Access | Times Cited: 96

Scroll to top